Your browser doesn't support javascript.
loading
ALSUntangled #68: ozone therapy.
Sun, Yuyao; Barkhaus, Paul; Barnes, Benjamin; Beauchamp, Morgan; Benatar, Michael; Bertorini, Tulio; Bromberg, Mark; Carter, Gregory T; Crayle, Jesse; Cudkowicz, Merit; Dimachkie, Mazen; Feldman, Eva L; Fullam, Timothy; Heiman-Patterson, Terry; Jhooty, Sartaj; Lund, Isaac; Mcdermott, Christopher; Pattee, Gary; Pierce, Kaitlyn; Ratner, Dylan; Wicks, Paul; Bedlack, Richard.
Afiliación
  • Sun Y; Neurology Department, University of Kentucky, Lexington, KY, USA.
  • Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Barnes B; Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
  • Beauchamp M; Neurosciences Clinical Trials Unit, UNC Chapel Hill NC, Chapel Hill, NC, USA.
  • Benatar M; Department of Neurology, University of Miami, Miami, FL, USA.
  • Bertorini T; Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA.
  • Carter GT; Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
  • Crayle J; Neurology Department, Washington University, St. Louis, MO, USA.
  • Cudkowicz M; Department of Neurology, Harvard Medical School, Boston, MA, USA.
  • Dimachkie M; Department of Neurology, University of Kansas, Kansas City, KS, USA.
  • Feldman EL; Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  • Fullam T; Department of Neurology, UTSA, San Antonio, TX, USA.
  • Heiman-Patterson T; Department of Neurology, Temple Health, Philadelphia, PA, USA.
  • Jhooty S; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Lund I; Green Hope High School, Cary, NC, USA.
  • Mcdermott C; Department of Neuroscience, University of Sheffield, Sheffield, UK.
  • Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Pierce K; Department of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ratner D; Longmeadow High School, Longmeadow, MA, USA.
  • Wicks P; Independent Consultant, Lichfield, UK.
  • Bedlack R; Department of Neurology, Duke University, Durham, NC, USA.
Amyotroph Lateral Scler Frontotemporal Degener ; 24(5-6): 548-552, 2023 08.
Article en En | MEDLINE | ID: mdl-36398749
ABSTRACT
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review ozone therapy. Ozone therapy has possible mechanisms for slowing ALS progression based on its antioxidant, anti-inflammatory, and mitochondrial effects. A non-peer-reviewed report suggests that ozone treatment may slow progression in a mTDP-43 mouse model of ALS. One verified "ALS reversal" occurred on a cocktail of alternative treatments including ozone. There are no ALS trials using ozone to treat PALS. There can be potentially serious side effects associated with ozone therapy, depending on the dose. Based on the above information, we support an investigation of ozone therapy in ALS cell or animal models but cannot yet recommend it as a treatment in PALS.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral Límite: Animals / Humans Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral Límite: Animals / Humans Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos